PeptideDB

DL-Buthionine-(S,R)-sulfoximine hydrochloride (Buthionine sulfoximine hydrochloride; BSO hydrochlori

DL-Buthionine-(S,R)-sulfoximine hydrochloride (Buthionine sulfoximine hydrochloride; BSO hydrochlori

CAS No.:

DL-Buthionine-(S,R)-sulfoximineHCl (Buthionine sulfoximineHCl) is a potent inhibitor of glutamylcysteine synthetase bios
Sales Email:peptidedb@qq.com

This product is for research use only, not for human use. We do not sell to patients.

DL-Buthionine-(S,R)-sulfoximine HCl (Buthionine sulfoximine HCl) is a potent inhibitor of glutamylcysteine synthetase biosynthesis.

Physicochemical Properties


Molecular Formula C8H19CLN2O3S
Molecular Weight 258.77
Related CAS # DL-Buthionine-(S,R)-sulfoximine;5072-26-4;L-Buthionine-(S,R)-sulfoximine hydrochloride
Appearance Typically exists as solid at room temperature
HS Tariff Code 2934.99.9001
Storage

Powder-20°C 3 years

4°C 2 years

In solvent -80°C 6 months

-20°C 1 month

Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light.
Shipping Condition Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

Biological Activity


Targets Glutamylcysteine synthetase[1]
ln Vitro Buthionine sulfoximine is a methionine sulfoximine analog that inhibits gamma-glutamylcysteine synthetase more than prothionine sulfoximine by at least 100 times and more than 20 times, respectively[1].
ln Vivo Continuous intravenous infusion of nontoxic doses of D,L-Buthionine-(S,R)-sulfoximine (300 and 600 mg/kg/day) in mice harboring HT1080 and HT1080/DR4 xenografts results in a 60% decrease in GSH plasma levels and a greater than 95% reduction in GSH tumor levels in both parental and multidrug-resistant tumors[2].
References

[1]. Potent and specific inhibition of glutathione synthesis by buthionine sulfoximine (S-n-butyl homocysteine sulfoximine). J Biol Chem. 1979 Aug 25;254(16):7558-60.

[2]. d,l-buthionine-(S,R)-sulfoximine potentiates in vivo the therapeutic efficacy of doxorubicin against multidrug resistance protein-expressing tumors. Clin Cancer Res. 1996 Dec;2(12):1961-8.


Solubility Data


Solubility (In Vitro) H2O :~100 mg/mL (~386.44 mM)
DMSO :< 1 mg/mL
Solubility (In Vivo) Solubility in Formulation 1: 100 mg/mL (386.44 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.

 (Please use freshly prepared in vivo formulations for optimal results.)
Preparing Stock Solutions 1 mg 5 mg 10 mg
1 mM 3.8644 mL 19.3222 mL 38.6444 mL
5 mM 0.7729 mL 3.8644 mL 7.7289 mL
10 mM 0.3864 mL 1.9322 mL 3.8644 mL
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.